Second cancer after treatment of malignant germ-cell tumors

World J Urol. 1994;12(3):151-4. doi: 10.1007/BF00192277.

Abstract

Patients cured of a malignant germ-cell tumor are at a significantly increased relative risk (RR, 1.3-2.1) of developing a new malignancy, the most frequent second cancer being a new germ-cell cancer. The exact role of modern treatment of germ-cell malignancies as an etiological factor of a subsequent cancer has not yet been defined. The relative risk of developing a new non-germ-cell cancer, however, seems especially high after intensive cytotoxic treatment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Carcinoma in Situ / blood
  • Carcinoma in Situ / epidemiology
  • Carcinoma in Situ / pathology*
  • Carcinoma in Situ / therapy
  • Combined Modality Therapy
  • Diagnosis, Differential
  • Follicle Stimulating Hormone / blood
  • Follow-Up Studies
  • Germinoma / blood
  • Germinoma / epidemiology
  • Germinoma / pathology*
  • Germinoma / therapy
  • Humans
  • Male
  • Neoplasm Invasiveness
  • Neoplasms, Second Primary / blood
  • Neoplasms, Second Primary / epidemiology
  • Neoplasms, Second Primary / pathology*
  • Neoplasms, Second Primary / therapy
  • Orchiectomy
  • Radiotherapy Dosage
  • Risk Factors
  • Testicular Neoplasms / blood
  • Testicular Neoplasms / epidemiology
  • Testicular Neoplasms / pathology*
  • Testicular Neoplasms / therapy
  • Time Factors

Substances

  • Biomarkers, Tumor
  • Follicle Stimulating Hormone